Archive | December, 2015

Heighten Your Visibility at the Redefining Early Stage Investments Conference (RESI)

3 Dec

By Dr. William Kohlbrenner, CSO, LSN

bill-1010-2wp

JPM turns San Francisco into an industry hub every January, and it’s strategically vital to make your company shine during the biggest and busiest yearly event attended by investors and life science entrepreneurs.  While there are many conferences and receptions taking place, there are relatively few opportunities for promoting your company’s brand among qualified life science investors.

That’s why we designed the RESI Innovation Challenge to provide a better showcase for life science companies. By providing space in the RESI Exhibit Hall for successful applicants to place poster displays, the RESI Innovation Challenge puts your brand out there throughout the full-day event, keeping you on view for the hundreds of investors who will be attending RESI throughout the day. More importantly, your message will provide a talking point that can springboard conversations about your technology, your market opportunity, and your company’s progress. Even if you’re out doing a full tour of meetings, your message will still be getting out there in the RESI Exhibit Hall. If you place in the top 3 participating companies, LSN will also showcase you online in Next Phase.

With the RESI Innovation Challenge deadline coming up on December 9th, LSN would like to encourage you to put your company in the spotlight. We’ve seen some very impressive applications thus far, and we hope to receive many more by the deadline next week. We’re excited to get this look into emerging technologies, and LSN’s scientific review board will assess every application to select the 30 best entrants to be part of the RESI Innovation Challenge.

As always, we welcome a broad variety of life science startups to apply; past RESI winners have come from all over the map, including companies developing products in biotech, healthcare IT, diagnostics, and personalized medicine. With the deadline a week away, we’re looking forward to receiving your application.

RESI-SF-2016-RESI-Innovation-Challenge

Tags:

RESI Panel Announcement: Diagnostic Investors

3 Dec

By Nicholas Civitarese, Research Analyst, LSN

nick-wp

The amount of capital being invested in medical technology and diagnostics is at its highest point since 2008. However, companies in the diagnostics space face some unique challenges in the fundraising landscape.

To inform your fundraising campaign’s direction, Life Science Nation is pleased to announce a panel of six investors with expertise in the diagnostics space for RESI San Francisco on January 12th. Moderated by Akhil Saklecha, Partner at Artiman Ventures, the panel will feature:

This panel will provide fundraising entrepreneurs with an inside peak into the strategy of these diagnostic investors – including best practices for building relationships with diagnostic investors as well as advice on making sure your diagnostic company is positioned as a strong investment opportunity.

If you’re interested in listening to this panel live at RESI, you can register for RESI San Francisco now. RESI provides a great opportunity to expand your network in the life sciences and to get a better understanding of fundraising process, and January 12th will be our largest gathering yet.

RESI-San-Francisco-2016

Tags: , , , , , , ,

Hot Life Science Investor Mandate 1: Billion Dollar China VC Seeks Novel Medical Devices & Reformulated Drug Opportunities

3 Dec

A venture capital firm with offices throughout China manages about USD 1 billion in committed capital with three USD funds and three RMB funds. The firm typically invests in series A and B rounds. The firm can invest anywhere from a few hundred thousand dollars up to ten million or more over a 10 year horizon. At present, the firm is looking for new investment opportunities in Greater China, while it also considers US- or EU-based companies that are Chinese-led or have a China angle.

The firm seeks to invest in a broad array of technologies including therapeutics, medical devices, IVD, healthcare big data and mHealth. Within therapeutics, the firm is interested in reformulated and generic drugs. The firm typically does not consider novel drugs. Within medical devices, the firm is interested in disposable devices and products that address large unmet medical need in China. The firm is opportunistic in terms of subsectors and stage of development. Historically, the firm invested in radiology imaging, clinical cell and molecular genetics testing, POC devices, mobile health, diagnostics and genomics, and drug discovery.

The firm is looking for competent and experienced management teams. The firm typically seeks a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 2: Corporate VC Seeks Imaging & Molecular Diagnostic Companies

3 Dec

A Germany-based corporate VC with offices worldwide invests in medical technology companies that are strategically relevant to its parent firm. Investments in equity rounds range from $1-5 million, and are made worldwide.

The fund’s primary focuses within healthcare are medical imaging (including both equipment and software) and diagnostics (particularly point of care diagnostics and molecular diagnostics). In these sectors, the fund focuses on products used in a hospital setting. The fund also invests in healthcare IT solutions that add value to imaging and diagnostics, such as data-as-a-service products. The fund is potentially interested in medical robotics. The fund will invest in any medical indication area, and only invests in companies that have attained proof of concept data for their product, with a preference for companies that have a product on the market that can demonstrate traction and revenue.

The fund generally does not attach strategic rights to an investment other than the right to be informed if the company is seeking a buyer. The firm requires a board seat or a board observer in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 3: Swiss Investment Fund Seeks Clinical-Stage Therapeutics, Diagnostics & Devices

3 Dec

A publicly-traded investment fund founded in 2001 and based in Switzerland invests in life science companies at both the developmental stage and also the growth/expansion stage, and usually makes 5-6 venture investments per year with half of their capital being deployed in the U.S. Only pre-clinical opportunities that are close to entering the clinic will be considered, however an exception may be made for novel/breakthrough science that has the possibility for a large syndicate. The firm’s early-stage investments are typically $5M-1$0M, and later-stage investments range from $10M-$25M. The firm invests primarily in Europe and the USA, but has also invested in Canada and is open to opportunities in the Middle East.

The firm invests primarily in therapeutics and is also interested in diagnostics, devices, and technologies with the potential to lead to therapeutic development (eg. drug discovery platforms). In the therapeutics field, the firm generally invests in clinical-stage opportunities. The firm invests in therapeutic areas where a result can be achieved with a reasonable amount of money, and therefore does not invest in highly capital-intensive therapeutic markets such as cardiovascular diseases, or large markets in metabolic disease such as diabetes or high cholesterol (smaller markets within metabolic disease may be of interest). Similarly, the fund typically avoids fields that are less well understood, such as CNS disorders or psychiatry. The firm is open to investing in orphan diseases.

In the devices and diagnostics field, the firm is open to investing in both companies with products under development and also companies with approved products that require commercialization-stage capital. For diagnostics, the firm focuses on innovative diagnostic technologies including biomarkers. As for medical devices, the firm focuses on devices that have a therapeutic application, including delivery devices, cardiac devices, and catheters; the firm prefers to invest in devices that require regulatory approval (Class 2 and 3 devices), rather than less regulated or disposable medical devices.

The firm invests in both private and public companies. Only U.S. companies with a headquarters on the West or East coast are considered. The fund has no fixed requirements for entrepreneurs but prefers to work with experienced management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 4: China Fund & Strategic Advisor Seeking Global Life Science Opportunities

3 Dec

A strategic consulting firm has a venture capital arm with offices in the US Midwest and Shanghai, China. Alongside investments, the firm advises life science companies on strategic partnerships (manufacturers, distributors) in the China market by providing resources in the network. The firm is currently raising a fund predicted to close mid-year 2016. The firm is seeking five new investments within the next year, and typically makes $1M to several million dollar investments per company in Series A, B, and C rounds. The firm focuses on US-based companies, though is open to companies on a global-level.

The firm is indication agnostic and open to technology in all sectors of life science – medical devices, therapeutics, diagnostics, and healthcare IT. In terms of phase of development, the firm requires the company to at least have a prototype, and for therapeutics to be in clinical trials, preferably in Series B. The firm will also look at on-the-market products as well as lab equipment and drug development enabling technology.

The firm requires the company to be in Series A, B, or C. The firm prefers the company to have or seek to have their technology in the China market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Newer Entries →